PHILADELPHIA, Nov. 26, 2018 /PRNewswire/ -- Aevi
Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company)
announced today that the Aevi Genomic Medicine Management team will
host a breakfast with Key Opinion Leader (KOL) Robert Findling,
M.D., Leonard and Helen R. Stulman Professor in Child and
Adolescent Psychiatry at Johns Hopkins University. During the
breakfast they will discuss the diagnosis and treatment paradigms
in Attention Deficit Hyperactivity Disorder (ADHD). The
breakfast is being held on Thursday,
November 29, 2019 at 8:00 AM
EST at the National in New York,
New York.
A live webcast of the presentation can be accessed under
"Presentations" in the Investors section of the Company's website
at www.aevigenomics.com or you may use the link:
http://media.rampard.com/20181129/reg.jsp
About Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. is dedicated to unlocking the
potential of genomic medicine to translate genetic discoveries into
novel therapies. Driven by a commitment to patients with pediatric
onset life-altering diseases, the Company's research and
development efforts leverage an internal genomics platform and an
ongoing collaboration with the Center for Applied Genomics (CAG) at
The Children's Hospital of Philadelphia (CHOP).
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, status and timing of clinical trials, its development and
business strategy, its product candidates and the plans and
objectives of management for future operations. The Company intends
that such forward-looking statements be subject to the safe harbors
created by such laws. Forward-looking statements are sometimes
identified by their use of the terms and phrases such as
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning, "expect," "believe," "will," "will likely," "should,"
"could," "would," "may" or the negative of such terms and other
comparable terminology. All such forward-looking statements are
based on current expectations and are subject to risks and
uncertainties. Should any of these risks or uncertainties
materialize, or should any of the Company's assumptions prove
incorrect, actual results may differ materially from those included
within these forward-looking statements. Accordingly, no undue
reliance should be placed on these forward-looking statements,
which speak only as of the date made. The Company expressly
disclaims any obligation or undertaking to disseminate any updates
or revisions to any forward-looking statements contained herein to
reflect any change in the Company's expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based. As a result of these factors,
the events described in the forward-looking statements contained in
this release may not occur.
CONTACT:
Aevi Genomic Medicine, Inc.
Brian Piper
Brian.Piper@aevigenomics.com
Westwicke Partners
Chris Brinzey
339-970-2843
Chris.brinzey@westwicke.com
View original
content:http://www.prnewswire.com/news-releases/aevi-genomic-medicine-to-host-kol-breakfast-to-discuss-diagnosis-and-treatment-paradigms-in-adhd-300754327.html
SOURCE Aevi Genomic Medicine, Inc.